---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-001989"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:10:11.993069+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ironwood guides FY2024 adj EBITDA >$150M, LINZESS low-single digit growth, pipeline catalysts

## Summary
- Maintains FY2023 guidance: LINZESS net sales growth 6-8%, revenue $435-450M, adjusted EBITDA ~($900M) from VectivBio charge.
- FY2024 guidance: LINZESS U.S. net sales low-single digit % growth, total revenue $435-455M, adjusted EBITDA >$150M.
- Expects apraglutide STARS Phase 3 topline data in SBS-IF in March 2024; CNP-104 Phase 2 topline data in PBC in Q3 2024.
- High-single digit LINZESS prescription demand growth in 2024 offset by mid-to-high single digit price erosion from Medicaid AMP cap removal.

## SEC filing metadata
- accession: 0001104659-24-001989
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465924001989/0001104659-24-001989-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465924001989/tm242140d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-001989
- JSON: https://secwatch.observer/filing/0001104659-24-001989.json
- Plain text: https://secwatch.observer/filing/0001104659-24-001989.txt

## Key facts
- Earnings Releases
  IRONWOOD PHARMACEUTICALS INC reported full year 2024 results: revenue $435 - $455 million. Guidance initiated.
  - Period: full year 2024
  - Revenue: $435 - $455 million
  - Guidance: initiated
  - Result: guidance update
  source text: - 8% Low-single digits % High-single digit prescription demand growth offset by mid to high-single digit price erosion primarily due to Medicaid AMP cap removal Total revenue $435 - $450 million $435 - $455 million Adjusted EBITDA 1 ~($900) million Reflects ~$1.1 billion one-time charge from acquisition of VectivBio >$150 million Excludes potential
  evidence_url: https://www.sec.gov/Archives/edgar/data/1446847/000110465924001989/0001104659-24-001989-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.